Search
forLearn
5 / 801 resultslearn Vascular Endothelial Growth Factor
learn Keraguard
learn Synergen Complex ®
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Research
5 / 1000+ resultsresearch Epigenetic Mechanisms, Assessment and Therapeutics of Epidermal Stem Cells in Skin Aging
Epigenetic changes in skin cells contribute to aging, but targeting these changes may offer new antiaging treatments.
research Predicting Physical Appearance from Low Template: State of the Art and Future Perspectives
Machine learning improves DNA predictions for eye and hair color, but challenges remain for skin tone and facial features.
research Recent advances in Forensic DNA Phenotyping of appearance, ancestry and age
Forensic DNA Phenotyping can now better predict appearance, ancestry, and age from DNA, but more research is needed for precise police use.
research DNA phenotyping: current application in forensic science
DNA phenotyping helps predict physical traits from DNA with varying accuracy and requires careful ethical and legal handling.
research Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
Community Join
5 / 1000+ resultscommunity Why is Kevin Mann (Haircafe) Hated?
Hair loss treatments, including microneedling, minoxidil, finasteride and RU58841; the efficacy of these treatments; criticisms of Kevin Mann's content related to his selective data presentation and biases towards certain treatments; and other topics such as DHT being labeled a "trash hormone" and critiques of other hairloss YouTubers.
community Verteporfin (Visudyne) group buy 🌷
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.
community Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
community Best Treatment In The Pipeline?
New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.
community Has anyone used ru58841 from vantanex?
RU58841 from Vantanex is discussed for hair loss treatment. Users share experiences and question its legitimacy.